Literature DB >> 19679214

Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion.

Susan L Baldwin1, Narek Shaverdian, Yasuyuki Goto, Malcolm S Duthie, Vanitha S Raman, Tara Evers, Farah Mompoint, Thomas S Vedvick, Sylvie Bertholet, Rhea N Coler, Steven G Reed.   

Abstract

Impairments in anti-influenza T helper 1 (Th1) responses are associated with greater risk of influenza-related mortality in the elderly. Addition of adjuvants to existing influenza vaccines could improve immune responses in the elderly. In this study, the activity of three adjuvants, an oil-in-water emulsion and a synthetic lipid A adjuvant formulated with or without the emulsion, is compared. Our results show that Fluzone combined with lipid A plus an emulsion effectively leads to greater vaccine-specific IgG2a and IgG titers, enhances hemagglutination-inhibition titers and induces Type 1 cytokine responses (IFN-gamma and IL-2) to each of the Fluzone components.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19679214     DOI： 10.1016/j.vaccine.2009.07.081

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  56 in total

Review 1.  Use of defined TLR ligands as adjuvants within human vaccines.

Authors:  Malcolm S Duthie; Hillarie Plessner Windish; Christopher B Fox; Steven G Reed
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

2.  A new synthetic TLR4 agonist, GLA, allows dendritic cells targeted with antigen to elicit Th1 T-cell immunity in vivo.

Authors:  Austin Pantel; Cheolho Cheong; Durga Dandamudi; Elina Shrestha; Saurabh Mehandru; Luke Brane; Darren Ruane; Angela Teixeira; Leonia Bozzacco; Ralph M Steinman; M Paula Longhi
Journal:  Eur J Immunol       Date:  2011-12-12       Impact factor: 5.532

3.  A TLR4 agonist synergizes with dendritic cell-directed lentiviral vectors for inducing antigen-specific immune responses.

Authors:  Liang Xiao; Jocelyn Kim; Matthew Lim; Bingbing Dai; Lili Yang; Steven G Reed; David Baltimore; Pin Wang
Journal:  Vaccine       Date:  2012-02-05       Impact factor: 3.641

4.  In vitro evaluation of TLR4 agonist activity: formulation effects.

Authors:  Ayesha Misquith; H W Millie Fung; Quinton M Dowling; Jeffrey A Guderian; Thomas S Vedvick; Christopher B Fox
Journal:  Colloids Surf B Biointerfaces       Date:  2013-09-19       Impact factor: 5.268

5.  Intratumoral immune activation with TLR4 agonist synergizes with effector T cells to eradicate established murine tumors.

Authors:  Tina C Albershardt; Jardin Leleux; Andrea J Parsons; Jordan E Krull; Peter Berglund; Jan Ter Meulen
Journal:  NPJ Vaccines       Date:  2020-06-16       Impact factor: 7.344

6.  Immunisation with ID83 fusion protein induces antigen-specific cell mediated and humoral immune responses in cattle.

Authors:  Gareth J Jones; Sabine Steinbach; Derek Clifford; Susan L Baldwin; Gregory C Ireton; Rhea N Coler; Steven G Reed; H Martin Vordermeier
Journal:  Vaccine       Date:  2013-09-05       Impact factor: 3.641

7.  Evaluating the efficacy of rBmHATαc as a multivalent vaccine against lymphatic filariasis in experimental animals and optimizing the adjuvant formulation.

Authors:  Gajalakshmi Dakshinamoorthy; Ramaswamy Kalyanasundaram
Journal:  Vaccine       Date:  2013-11-06       Impact factor: 3.641

8.  Protection and Long-Lived Immunity Induced by the ID93/GLA-SE Vaccine Candidate against a Clinical Mycobacterium tuberculosis Isolate.

Authors:  Susan L Baldwin; Valerie A Reese; Po-Wei D Huang; Elyse A Beebe; Brendan K Podell; Steven G Reed; Rhea N Coler
Journal:  Clin Vaccine Immunol       Date:  2015-12-09

9.  MyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvant.

Authors:  Mark T Orr; Malcolm S Duthie; Hillarie Plessner Windish; Elyse A Lucas; Jeffrey A Guderian; Thomas E Hudson; Narek Shaverdian; Joanne O'Donnell; Anthony L Desbien; Steven G Reed; Rhea N Coler
Journal:  Eur J Immunol       Date:  2013-07-03       Impact factor: 5.532

10.  Adjuvant solution for pandemic influenza vaccine production.

Authors:  Christopher H Clegg; Richard Roque; Neal Van Hoeven; Lucy Perrone; Susan L Baldwin; Joseph A Rininger; Richard A Bowen; Steven G Reed
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-08       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.